RCT | Effect of low-concentration atropine eyedrops vs. placebo on myopia incidence in children

Summary: The study aimed to evaluate the efficacy of low-concentration atropine eyedrops at 0.05% and 0.01% concentration for delaying the onset of myopia in children. The randomized, placebo-controlled, double-masked trial enrolled 474 nonmyopic children aged 4 through 9 years. Participants were assigned to 0.05% atropine, 0.01% atropine, and placebo groups and had eyedrops applied once nightly in both eyes over 2 years. The results showed that the 0.05% atropine eyedrops resulted in a significantly lower incidence of myopia and a lower percentage of participants with fast myopic shift at 2 years compared with placebo. However, there was no significant difference between 0.01% atropine and placebo. More research is necessary to replicate the results, determine whether this approach delays or prevents myopia, and evaluate its long-term safety.*

Article: Effect of Low-Concentration Atropine Eyedrops vs Placebo on Myopia Incidence in Children: The LAMP2 Randomized Clinical Trial – JAMA (free for a limited period)

Editorial: Delaying the Onset of Nearsightedness – JAMA (free for a limited period)

Commentaries:

Atropine Eyedrops Associated With Lower Incidence of Myopia, Myopic Shift – AJMC

Low-Concentration Atropine Eyedrops Linked to Lower Myopia Incidence in Children – HCP Live

0.05 Percent Atropine Eye Drops Result in Lower Incidence of Myopia – HealthDay

Commentary on Twitter

Among children aged 4 to 9 years without #myopia, nightly use of 0.05% atropine eyedrops compared with placebo resulted in a significantly lower incidence of myopia and lower percentage of participants with fast myopic shift at 2 years. https://t.co/XUjnPVGVad pic.twitter.com/4iZa4Iek76

— JAMA (@JAMA_current) February 14, 2023

*Note: This summary was created through the collaboration of a medical editor and ChatGPT.